ADCYAP1R1 and neoplasm: The administration of a PAC1R antagonist, PACAP6-38, did not terminate this cytotoxic effect of PACAP38; furthermore, PACAP6-38 alone, in the same micromolar concentration, also produced a dose-dependent decrease in tumor cell viability.